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Abstract
Background: The ASTRAL trial showed no difference in clinical outcomes between medical therapy and
revascularization for atherosclerotic renal vascular disease (ARVD). Here we report a sub-study using
echocardiography to assess differences in cardiac structure and function at 12 months.
Methods: ASTRAL patients from 7 participating centres underwent echocardiography at baseline and 12 months
after randomisation. Changes in left ventricular ejection fraction (LVEF), left ventricular mass (LVM), left atrial
diameter (LAD), aortic root diameter (AoRD), E:A, and E deceleration time (EDT) were compared between study
arms. Analyses were performed using t-tests and multivariate linear regression.
Results: Ninety two patients were included (50 medical versus 42 revascularization). There was no difference
between arms in any baseline echocardiographic parameter. Comparisons of longitudinal changes in
echocardiographic measurements were: δLVEF medical 0.8 ± 8.7% versus revascularization − 2.8 ± 6.8% (p = 0.05),
δLVM − 2.9 ± 33 versus − 1.7 ± 39 g (p = 0.9), δLAD 0.1 ± 0.4 versus 0.01 ± 0.5 cm (p = 0.3), δAoRD 0.002 ± 0.3 versus
0.06 ± 0.3 cm (p = 0.4), δE:A − 0.0005 ± 0.6 versus 0.03 ± 0.7 (p = 0.8), δEDT − 1.1 ± 55.5 versus − 9.0 ± 70.2 ms (p = 0.6).
In multivariate models, there were no differences between treatment groups for any parameter at 12 months.
Likewise, change in blood pressure did not differ between arms (mean δsystolic blood pressure medical 0 mmHg
[range − 56 to + 54], revascularization − 3 mmHg [− 61 to + 59], p = 0.60).
Conclusions: This sub-study did not show any significant differences in cardiac structure and function
accompanying renal revascularization in ASTRAL. Limitations include the small sample size, the relative insensitivity
of echocardiography, and the fact that a large proportion of ASTRAL patient population had only modest renal
artery stenosis as described in the main study.
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Background
The presence of atherosclerotic renovascular disease
(ARVD) in patients with chronic kidney disease (CKD)
presents an increased risk of cardiovascular morbidity
compared to other causes of CKD. ARVD is typically
associated with extensive extra-renal atherosclerosis and
significant cardiovascular comorbidities; 91% of ARVD
patients have hypertension, 38% have clinical heart
failure, and 67% have coronary artery disease [1, 2].
As a result of these overlapping cardiovascular risk
factors, cardiac structural remodelling is almost ubiqui-
tous in ARVD. At least three-quarters of ARVD patients
have left ventricular hypertrophy and diastolic dysfunc-
tion on echocardiography [3]. Patients with ARVD have
58% greater LV mass than eGFR matched CKD controls
[3], and likewise greater LV mass than non-CKD hyper-
tension controls [4].
Two large clinical trials failed to show clinical benefit
of renal artery revascularization when used as first line
therapy for ARVD. The primary outcome measure of the
ASTRAL (Angioplasty and Stenting for Renal Artery Le-
sions) trial was longitudinal change in renal function,
while that of the CORAL (Cardiovascular Outcomes in
Renal Atherosclerotic Lesions) trial was a composite of
death or major morbidity from cardiovascular or renal
causes [5, 6].
Although revascularization does not benefit most pa-
tients, there are many documented cases of significant
clinical and cardiac structural changes soon after inter-
vention [7, 8]. These suggest that revascularization may
be of benefit either in specific ARVD sub-groups, or that
patients undergo significant cardiac remodelling after
renal artery revascularization that does not manifest as a
reduction in the acute events recorded as end-points in
clinical trials. Whilst reporting bias is certain in these
reports, flash pulmonary oedema is the only clinical
scenario that has attracted Class I recommendation for
revascularization [9, 10].
Flash pulmonary oedema is however the presenting
feature in only 12% of cases of ARVD [11], meaning that
the majority of patients with ARVD do not appear to
suffer acute decompensation of heart failure despite
underlying cardiac remodelling. In these patients, any
change in cardiac structure and function that may occur
as a result of revascularization might not manifest as a
reduction in the acute cardiovascular events measured
by ASTRAL and CORAL. It is therefore reasonable to
hypothesise that patients with ARVD and abnormal
hearts who do not present with flash pulmonary oedema
may show sub-clinical improvements in cardiac struc-
ture and function after revascularization compared to
standard medical therapy [12, 13].
Here we present findings from an echocardiographic
sub-study of the ASTRAL trial. The primary aim of this
study was to evaluate whether the addition of renal
artery revascularization to standard medical therapy led
to improvements in the cardiac structural and functional
abnormalities associated with ARVD, as found on echo-
cardiography, compared to standard medical therapy
alone. A secondary aim was to quantitatively describe
the natural progression of cardiac abnormalities in an
ARVD cohort, irrespective of therapy, and specifically in
patients for whom revascularization is not already
indicated.
Methods
The detailed method of patient selection and interven-
tion for ASTRAL has previously been published [5]. In
summary, ASTRAL was a multicentre, non-blinded
clinical trial comparing outcomes in ARVD between
patients randomised to receive either medical therapy or
medical therapy plus percutaneous renal artery revascular-
ization (Clinical Trials Registration ISRCTN59586944).
Ethical approval for ASTRAL was granted by the West
Midlands Multicentre Research Ethics Committee, UK
and the ethics committee relevant to each individual
participating study centre. Ethical permission for the
echocardiographic sub-study was obtained separately.
Support for the main ASTRAL trial was received from the
Medical Research Council UK, Kidney Research UK, and
Medtronic.
Patient selection
Patients were eligible for ASTRAL if they had at least
one renal artery with an atherosclerotic lesion suitable
for percutaneous revascularization and their managing
clinician was not convinced that revascularization was
essential. Patients were excluded if revascularization was
already indicated as per guidelines, if the patient had
undergone previous revascularization, or if the stenosis
was not atherosclerotic in origin. No patients on haemo-
dialysis were entered into the study, and because flash
pulmonary oedema is a long-standing agreed indication
for revascularization in ARVD, such patients were not
recruited to ASTRAL.
Patients from 7 centres participating in ASTRAL were
approached to take part in this cardiac sub-study
(Salford Royal Hospital, Manchester Royal Infirmary,
Royal Free London, Aberdeen Royal Infirmary, Derriford
Hospital Plymouth, Glasgow Royal Infirmary, University
Hospitals of Leicester). Patients were randomised 1:1
into the ASTRAL study to either revascularization or no
revascularization, and this also determined the rando-
mised treatment allocation of patients in the sub-study.
No specific exclusion criteria were applied to the
echocardiographic sub-study, and every patient provided
signed informed consent.
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Echocardiography protocol
Patients underwent a full cross-sectional transthoracic
echocardiogram within 6 weeks of enrolment and, if
randomised to revascularization, before they underwent
the procedure. A second transthoracic echocardiography
was obtained 1 year later. Scans were performed locally
at each participating centre by technicians accredited for
transthoracic echocardiography by the British Society for
Echocardiography. Interpretation was performed by a
single imaging consultant cardiologist blind to the date
of each scan and the participant’s randomised treatment
allocation.
All image acquisitions and measurements were per-
formed as recommended by the American Society of
Echocardiography [14] and have been described previ-
ously [15]. In brief, left ventricular end diastolic diameter
(LVEDD), LV end systolic diameter (LVESD), interven-
tricular and LV posterior wall thickness at end diastole
were measured from parasternal long-axis M mode re-
cordings of the LV. The modified biplane Simpson’s rule
was used to determine the LV ejection fraction, with
measurements averaged over three cardiac cycles. Pulsed
wave Doppler recordings at the mitral valve leaflet tips
in the apical four-chamber view were used to record
transmitral flow. Peak velocity of early filling (E), peak
velocity of atrial filling (A), the E/A ratio, E-deceleration
time (ms) and isovolumetric relaxation time (IVRT)
were measured. LV mass was calculated using the
Devereux Formula. LV regional wall motion was ana-
lysed visually using the standard 17-segment model
for qualitative analysis and wall motion was scored on
a 4-point scale (1 = normal wall motion, 2 = hypokin-
esis, 3 = akinesis, and 4 = dyskinesis). The wall motion
score index was calculated as an average of the indi-
vidual wall motion scores of each visualised segment.
Echocardiographic evaluation of the aorta was per-
formed in the parasternal long-axis and suprasternal
view with measures recorded at the tubular ascending
aorta. The severity of valve disease was determined
by the physician’s visual assessment and graded as
mild, moderate or severe [16].
Sample size
Sample size calculation was based on left ventricular end
diastolic diameter (LVEDD), one of the more sensitive
parameters of change in cardiac function over time, or
after intervention, and based upon change in LVEDD in
a previous study of 79 ARVD patients (mean LVEDD
5.37 ± 0.95 cm). To detect a 0.6 cm (SD 0.95) difference
between revascularization and control groups at a power
of 80%, 41 patients would be needed for each group with
an alpha of 0.05. At 90% power, patient numbers would
be 54 per group.
Statistical analysis
The main end-points were change from baseline to fol-
low up in each of the echocardiographic parameters
listed above. The two treatment groups of medical ther-
apy alone and medical therapy plus revascularization
were compared using 2-sample t-tests. Multivariate
linear regression models were then constructed to con-
sider the effects of other pre-specified clinically relevant
baseline variables on each of the echocardiographic
parameters at 12 months. Alongside treatment group,
the following variables were included in each model: age,
presence of diabetes, history of coronary heart disease,
systolic blood pressure, diastolic blood pressure, degree
of stenosis to most affected kidney, renal function using
eGFR, prescription of beta-blockers and renin angio-
tensin blockade and baseline ventricular measurement.
A p-value of < 0.05 was considered statistically
significant. All analyses were performed using SAS
version 9.1 (SAS Institute, Cary, NC, USA).
Results
There were 92 patients included in the study (50
medical, 42 revascularization). The two arms were
broadly comparable: the age in the medical arm was 71
years (range 51–86) compared with 70 (53–86) years in
the revascularization arm (p = 0.9). There was no differ-
ence in baseline eGFR, calculated using the Cockroft-
Gault equation: 43.0 (17.0–79.7) ml/min versus 44.7
(15.4–89.8) ml/min (p = 0.65). Similarly, there was no
difference in systolic blood pressure: 152 (90–220)
mmHg versus 146 (103–196) mmHg (p = 0.36). A full
comparison of baseline characteristics is found in
Table 1. The only difference between the arms was that
patients in the medical therapy group were more likely
to be on lipid lowering therapy than those in the revas-
cularization group (93% versus 78%, p = 0.04). However,
serum cholesterol was no different: 4.5 (2.8–7.9) mmol/
L versus 4.3 (2.3–6.5) mmol/L, p = 0.43.
The baseline echocardiographic measurements were
all comparable between groups, with none showing a
statistically significant difference. Systolic function was
well preserved overall (54 ± 10%). The complete list of
baseline echocardiographic variables is found in Table 2.
This table also shows the change in each parameter be-
tween baseline and follow up. There was no difference
between the medical and revascularization arms for lon-
gitudinal change in any echocardiographic parameter on
univariate analysis. These are detailed in full in Table 2.
LVEF was closest to showing a statistical difference
(medical 0.8 ± 8.7% versus revascularization − 2.8 ± 6.8%,
p = 0.05).
Importantly, allied to this, there was no change in
blood pressure between arms during follow up. In the
medical arm, the mean systolic blood pressure change
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during follow up was 0 mmHg (range − 56 to + 54
mmHg). This compared with a mean change of − 3 (− 61
to + 59) mmHg in the revascularization arm (p = 0.60).
For diastolic blood pressure, the respective changes were
0 (− 27 to + 80) mmHg versus − 4 (− 41 to + 20) mmHg
(p = 0.27).
Table 3 summarises the output of the multivariate
regression models for each of the echocardiographic
parameters. Treatment modality did not alter out-
come for any echocardiographic parameter including
left ventricular mass, volume and ejection fraction.
Other baseline factors did demonstrate significance,
particularly medication although no drugs were
consistently significant across all echocardiographic
parameters. Beta-blockade was associated with better
aortic root diameter at follow up, but higher left
ventricular mass and relative wall thickness. ACE in-
hibitor use was also associated with higher relative
wall thickness.
When comparing all follow up scans with all baseline
scans, there was no overall significant difference between
any individual parameter using paired t-test: LVEF
baseline = 54 ± 10% versus LVEF at follow up = 53 ± 9%,
p = 0.40; left atrial diameter = 4.0 ± 0.5 cm versus 4.0 ±
0.6 cm, p = 0.19; LVEDD = 4.9 ± 0.4 versus 4.8 ± 0.4, p =
0.07, LV mass = 206 ± 37 g versus 204 ± 37 g, p = 0.65. Al-
though the overall pattern was of no change, individual
cases did show deterioration or improvement in
Table 1 Baseline characteristics comparing medical therapy versus revascularization patients
Medical (N = 50) Revascularization (N = 42) p
Demographic
Mean age (range) – years 71 (51–86) 70 (53–86) 0.90
Male sex – no. (%) 34 (68%) 33 (79%) 0.26
Clinical
Smoking status – no./total no (%)
Current smoker 11/46 (24%) 8/36 (22%) 0.86
Former smoker 24/46 (52%) 19/36 (53%) 0.96
Coexisting conditions – no./total no (%)
Diabetes 15/47 (32%) 13/37 (35%) 0.76
Coronary heart disease 25/47 (53%) 22/37 (59%) 0.57
Peripheral vascular disease 20/46 (43%) 17/37 (46%) 0.82
Stroke 14/47 (30%) 8/37 (22%) 0.40
Need for dialysis 0 0 –
Renal Function
Mean serum creatinine (range) – μmol/litre 165 (64–326) 170 (68–534) 0.76
Mean eGFR (range) – ml/min 43.0 (17.0–79.7) 44.7 (15.4–89.8) 0.65
Mean proteinuria (range) – g/day 0.45 (0.01–2.20) 0.42 (0.00–1.70) 0.90
Related Measures
Mean systolic BP (range) – mmHg 152 (90–220) 146 (103–196) 0.36
Mean diastolic BP (range) – mmHg 74 (57–97) 74 (45–102) 0.93
Mean total cholesterol (range) – mmol/litre 4.5 (2.8–7.9) 4.3 (2.3–6.5) 0.43
Renal Physiology
Mean stenosis (range) – % 73.6 (50–99) 71.2 (50–95) 0.41
Severity of stenosis- no (%) 50–70% 26 (52%) 25 (60%) 0.47
> 70% 24 (48%) 17 (40%) –
Mean bipolar kidney length (range) – cm 9.6 (7.0–11.9) 9.7 (6.4–12.5) 0.70
Use of Concomitant medication
Mean no. of antihypertensive drugs (range) 3.0 (1–5) 2.9 (1–5) 0.66
Any antiplatelet drug – no./total no. (%) 38/47 (81%) 31/37 (84%) 0.73
Lipid lowering therapy – no./total no. (%) 43/46 (93%) 29/37 (78%) 0.04
Warfarin – no./total no. (%) 2/47 (4%) 5/36 (14%) 0.12
Key: BP blood pressure, eGFR estimated glomerular filtration rate
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structure or function on echocardiography, albeit with-
out a difference between the treatment arms as outlined
above. The range of change in LVEF was − 19 to + 27%
(median 0%), for left atrial diameter was − 1.1 cm to + 1.4
cm (median 0 cm), for LVEDD was − 0.9 cm to + 1.0 cm
(median − 0.1 cm), and for LV mass was -101 g to + 129 g
(median 0 g).
Figure 1 shows the correlation between baseline mea-
surements of LVEF, left atrial diameter, LVEDD and LV
mass, and the change in these parameters at follow up
Table 2 Comparison of echocardiographic parameters at baseline between trial arms and comparison of the changes in
measurement on the follow up scans compared to baseline
Baseline Change at follow up
Medical Revasc Medical Revasc p
Aortic root diameter (cm) 3.1 ± 0.4 3.1 ± 0.4 0.002 ± 0.3 0.06 ± 0.3 0.4
LVOT velocity (m/s) 1.2 ± 0.2 1.2 ± 0.2 −0.02 ± 0.1 −0.03 ± 0.1 0.7
LV ejection fraction (%) 53.8 ± 10.5 53.6 ± 9.2 0.8 ± 8.7 −2.8 ± 6.8 0.05
Left atrial diameter (cm) 3.8 ± 0.5 3.9 ± 0.5 0.1 ± 0.4 0.01 ± 0.5 0.3
LVESD (cm) 2.8 ± 0.6 2.8 ± 0.5 − 0.07 ± 0.4 0.1 ± 0.6 0.1
LVEDD (cm) 4.9 ± 0.4 4.9 ± 0.4 − 0.08 ± 0.4 − 0.07 ± 0.4 0.9
Left ventricular mass (g) 203 ± 37 202 ± 34 − 2.9 ± 33 −1.7 ± 39 0.9
Relative wall thickness 0.45 ± 0.08 0.44 ± 0.06 0.01 ± 0.06 0.01 ± 0.06 0.98
E:A 1.1 ± 0.6 1.1 ± 0.6 − 0.0005 ± 0.6 0.03 ± 0.7 0.8
E deceleration time (ms) 206 ± 59 202 ± 66 − 1.1 ± 55.5 −9.0 ± 70.2 0.6
Data are mean ± standard deviation
Key: revasc revascularization arm, LVOT left ventricular outflow tract, LV left ventricular, ESD end systolic diameter, EDD end diastolic diameter, n/s not significant
Table 3 Factors associated with echocardiographic measurements at follow up based on multivariate analysis
Measurement Significant factors Estimate Standard Error 95% CI p
AoRD Baseline AoRD 0.83 0.08 0.66 to 0.99 < 0.0001
Beta-blocker use - No 0.20 0.07 0.07 to 0.34 0.004
LVOT velocity Baseline LVOT velocity 0.73 0.08 0.58 to 0.88 < 0.0001
LVEF Baseline LVEF 0.61 0.08 0.45 to 0.77 < 0.0001
LA diameter Baseline LA diameter 0.88 0.11 0.67 to 1.10 < 0.0001
LVESD Baseline LVESD 0.51 0.08 0.34 to 0.67 < 0.0001
LVEDD Baseline LVEDD 0.52 0.08 0.35 to 0.68 < 0.0001
Age −0.01 0.005 −0.02 to − 0.0003 0.04
LV mass Baseline LV mass 0.60 0.09 0.42 to 0.77 < 0.0001
Coronary heart disease - No 20.1 6.54 7.02 to 33.19 0.003
eGFR −0.49 0.20 −0.89 to − 0.09 0.02
ACE inhibitor use - No −13.2 6.26 −25.74 to −0.68 0.04
E:A Baseline E:A 0.38 0.11 0.15 to 0.61 0.002
Diabetes - No −0.30 0.14 − 0.58 to − 0.01 0.04
EDT Baseline EDT 0.40 0.10 0.20 to 0.59 0.0001
Age 1.99 0.95 0.08 to 3.89 0.04
eGFR 0.93 0.38 0.17 to 1.68 0.01
RWT Baseline RWT 0.68 0.08 0.51 to 0.84 < 0.001
Beta-Blocker use - No −0.02 0.01 −0.04 to −0.001 0.04
ACE inhibitor use - No −0.03 0.01 −0.06 to − 0.01 0.003
Key: LVOT left ventricular outflow tract, LVEF left ventricular ejection fraction, LA left atrium, LVESD left ventricular end systolic diameter, LVEDD left ventricular end diastolic
diameter, EDT E wave deceleration time, RWT relative wall thickness, CI confidence intervals, eGFR estimated glomerular filtration rate, AoRD aortic root diameter
Each model included the following variables: treatment group, age, presence of diabetes, history of coronary heart disease, systolic blood pressure, diastolic blood
pressure, degree of stenosis to most affected kidney, renal function using eGFR, prescription of beta-blockers and renin angiotensin blockade and the baseline
ventricular measurement
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compared to baseline. For LVEF, 54% of patients with
preserved systolic function at baseline (LVEF≥50%) had
a worse LVEF at follow up. This compared with 24% of
patients who had pre-existing systolic impairment at
baseline (LVEF< 50%). The correlation coefficient be-
tween baseline LVEF and change in LVEF was − 0.53,
p < 0.01.
In a between group comparison of dLVEF between
those with preserved baseline LVEF (≥50% versus those
with reduced LVEF (< 50%) at baseline, the mean change
in the preserved function group was − 2.4 ± 6.4 mL
versus + 5.2 ± 10.5 mL in the reduced function group
(p = 0.01). The distribution was parametric.
For LA diameter, 54% of patients with a dilated left
atrium (diameter > 4 cm) at baseline showed an improve-
ment in diameter at follow up. The figure for baseline
normal left atrium was 25%. For change in left atrial
diameter against baseline reading, the correlation co-
efficient was − 0.16, p = 0.16. Only 5 patients had LVEDD
> 5.3 cm at baseline but all of these showed improvement
at follow up. Change in left ventricular mass followed a
similar pattern to that of LVEF (Fig. 1).
In a between group comparison of change in left
atrial diameter between those with normal baseline
diameter (< 4.0 cm) versus those with increased
diameter (≥4.0 cm), the mean change in the normal
group was + 0.1 ± 0.4 cm versus 0.0 ± 0.5 cm in the dilated
group (p = 0.201).
Discussion
This sub-study of a randomised clinical trial included 92
patients with ARVD and did not show any difference in
longitudinal change in echocardiographic parameters be-
tween patients treated with renal artery revascularization
versus those given medical therapy alone. This is con-
sistent with the cardiovascular end point findings of the
main ASTRAL [5] (hazard ratio for cardiovascular
events 0.94, 95% CI 0.75–1.19, p = 0.61) and CORAL [6]
studies (hazard ratio for composite primary end-point
0.94; 95% CI 0.76–1.17; p = 0.58).
Our findings are consistent with two other randomised
clinical trials. A recent parallel ASTRAL sub-study
investigated the effects of revascularization on cardiac
structure and function using cardiac magnetic resonance
imaging in 18 patients treated exclusively medically and
23 patients who underwent revascularization in addition
to treatment with medical therapy. Although slight
improvements in cardiac structural parameters were
seen in both groups at 12 months follow-up, there were
no significant differences between groups (change in
Fig. 1 Correlation between change in echocardiographic measurements at 1 year compared to baseline measurement for a) left ventricular (LV)
ejection fraction, b) left atrial diameter, c) left ventricular mass, d) left ventricular end diastolic diameter (LVEDD)
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LVM in medical versus revascularized group: − 5.4 g ver-
sus − 6.3 g, p = 0.8) [17]. The stenting of Renal Artery
Stenosis in Coronary Artery Disease (RAS-CAD) study
is another randomised trial that explored the effect of
revascularization on LVMI in ARVD patients with mean
renal artery stenosis < 70%, mean eGFR > 60.0 ml/min/
1.73m2 and well-controlled blood pressure; patients in
both arms were established on multi-targeted medical
therapy. Revascularization was shown to have no
additional impact on cardiac structure and blood pres-
sure control beyond optimal medical therapy. However,
there was again significant equivalent improvement in
blood pressure control and LVMI in both revascularized
(n = 43) and non-revascularized patients (n = 41) [18].
In contrast, in our study there was no overall differ-
ence in parameters at follow up compared to baseline.
Previous small non-randomised studies had demon-
strated improvement in left ventricular mass in patients
with renovascular hypertension or haemodynamically
significant stenosis. In two of these studies, this was
shown to correlate with improvement in blood pressure
control [19, 20]. In ASTRAL, including this sub-study,
there was no difference in blood pressure control
between treatment arms. This likely explains the lack of
any difference in δLVM seen here.
Although a lack of longitudinal improvement was
noted in this study, which differs from the results of
ASTRAL cardiac magnetic resonance imaging sub-study
and RAS-CAD [17, 18], this is not surprising given the
relative insensitivity of transthoracic echocardiography
for certain measurements (e.g. LV mass) compared to
cardiac magnetic resonance imaging. Left ventricular
mass was not adjusted for height and weight due to
missing data hence this may also have contributed to re-
duced accuracy. Regardless, the outcome measurement
is change in cardiac mass over time for each individual
patient. Given this, it is unlikely that there would be any
additional benefit to indexing these measurements
against body surface area or height.
In view of the lack of measurable longitudinal
changes observed in our study, we support the
current view that optimised medical therapy is as
effective as revascularization for routine ARVD ther-
apy, except in those patients for whom revasculariza-
tion is already indicated. Indeed, in the current study
we provided examples of patients who showed defin-
ite improvement or stabilisation in echocardiographic
parameters at 1 year, and likewise some with evi-
dence of deterioration and this is of clinical import-
ance. This comment is made notwithstanding the
possibility that the longitudinal changes seen repre-
sent regression to the mean in a population with a
broad baseline measurement in echocardiographic
descriptors.
Our results suggest a weak inverse correlation between
baseline function and improvement at 1 year, in keeping
with results from observational studies showing that re-
vascularization only appears to be of benefit in a small
subset of ‘high-risk’ patients [11, 21, 22]. Future research
efforts are likely to be directed towards the timely identi-
fication of these individuals through risk stratification
techniques with the aim of improving patient selection
for revascularization.
In our study, beta-blockade was associated with reduc-
tion in aortic root diameter. In light of the predomin-
ance of diastolic dysfunction in patients with ARVD [3],
this is presumed to be a function of blood pressure re-
duction and consequent improved diastolic function,
though we have no direct evidence of causation from
this trial. Beta-blockers have been consistently shown to
prevent adverse cardiac remodelling and optimise clin-
ical outcomes in patients with reduced ejection fractions
[23–25], although there is a concern that in patients
with heart failure with preserved ejection fraction
(HFpEF) beta-blockers can precipitate a negative
chronotropic effect and reduced exercise tolerance [26].
Their value in patients with non-ischaemic heart failure
with preserved ejection fraction has however not been
studied. Given the upregulated sympathetic drive and
the high rate of co-existent cardiovascular disease in
ARVD patients [1], our findings point towards the use of
such therapy in these patients. Indeed, a recent retro-
spective analysis performed on 529 patients with ARVD
showed that over a median follow-up period of 3.8 years,
beta-blockade was associated with reduced risk of death
(relative risk 0.52 [95% CI 0.31–0.89], p = 0.02) and
nonfatal cardiovascular events (relative risk 0.74 [95% CI
0.60–0.90], p = 0.003) [27].
In the context of non-ARVD patients with hyperten-
sion and diastolic dysfunction without a clinical diagno-
sis of heart failure, angiotensin-receptor blockers have
been shown to reduce left ventricular mass and function
and improve exercise tolerance; the changes in RWT
observed in this study did not mirror this [28–30], but
renin-angiotensin blockade has been shown to be associ-
ated with improved clinical outcomes in observational
studies carried out in patients with ARVD [31, 32].
Given the existing knowledge of the pathophysiology of
diastolic dysfunction in these patients, renin-angiotensin
blockade remains part of the standard of care for these
patients.
This study has limitations. Due to the slightly lower
than expected number of patients, the study had 80%,
rather than 90%, power to detect differences of the
anticipated magnitude. Finally, as mentioned above, an
important consideration is that some patients recruited
into this study may have had clinical and haemodynam-
ically insignificant RAS and so these results are not
Green et al. BMC Nephrology          (2019) 20:220 Page 7 of 9
necessarily generalizable to all patients with ARVD,
particularly those with severe renal artery stenosis
presenting with heart failure and other high-risk clinical
phenotypes [11].
Conclusion
In this ASTRAL sub-study, there was no significant dif-
ference in longitudinal change in echocardiographic pa-
rameters between revascularized and non-revascularized
patients, nor between baseline and follow-up scans in
the study population as a whole. These results are
consistent with the neutral renal, cardiovascular and
mortality end-points observed in the main ASTRAL trial
and in the subsequent CORAL trial.
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ventricle; LVEDD: Left ventricular end diastolic diameter,; LVEF: Left
ventricular ejection fraction; LVESD: Left ventricular end systolic diameter,;
LVM: Left ventricular mass; LVOT: Left ventricular outflow tract; PDGF: Platelet
derived growth factor; RAS-CAD: Renal artery stenosis coronary artery
disease; RWT: Relative wall thickness; TGF-β: Transforming growth factor beta
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